Next, to investigate whether SNORA13 ASOs could be used to treat CRC tumor therapeutically, a subcutaneous xenograft tumor model was performed, and saline, control ASO (NC), 5-Fluorouracil (5-FU), SNORA13 ASO (ASO), and combined 5-FU with SNORA13 ASO were administrated respectively via intratumoral injection twice per week for consecutive 4 weeks (Figure 3E). The gene discussed is SNORA13; the disease is colorectal carcinoma.